OSSDSIGN AB

Their core work

OSSDSIGN AB is a Swedish medical device SME based in Uppsala that specializes in ceramic biomaterials for spinal and orthopedic implant applications. Their core work spans materials synthesis, mechanical characterization, surface coatings, and biological performance testing of ceramic compounds — notably silicon nitride and alumina — as implantable devices. They bring industrial product development expertise into academic research consortia, contributing practical knowledge about how ceramic materials perform under physiological conditions including wear, corrosion, and osseointegration. Their EU project participation indicates active investment in validating and advancing their implant materials through collaborative science with leading European research groups.

What they specialise in

How they've shifted over time

OSSDSIGN's earliest H2020 engagement (FRAMED, 2017) was grounded in broad fracture mechanics — modeling crack propagation, fatigue life, and stochastic failure across diverse material classes including biomaterials, civil engineering, and energy applications. By 2019, their focus had narrowed sharply with NU-SPINE: the keyword set shifted entirely to clinically specific topics — silicon nitride, alumina, osseointegration, spinal fusion, tribology, and wear — reflecting a pivot from general materials science toward product-relevant ceramic implant research. The trajectory is consistent with a medical device company using fundamental research participation early to build scientific credibility, then transitioning to domain-specific collaborative R&D that feeds directly into their implant product line.

OSSDSIGN AB is converging toward a tightly defined niche — high-performance ceramics for spinal surgery — suggesting future collaborations will center on clinical validation, regulatory evidence generation, and advanced surface engineering for osseointegration.

How they like to work

OSSDSIGN has never led an H2020 project, consistently joining as a participant or third-party partner — the typical posture of an industrial SME that contributes application-specific expertise rather than administrative coordination. Their involvement in two MSCA programs (RISE for researcher exchanges, ITN for doctoral training) shows they are specifically valued as industry hosts and advisors rather than as grant managers. Both consortia were large, multi-country networks, demonstrating comfort operating inside complex distributed research structures without holding the steering role.

Despite only two projects, OSSDSIGN has engaged with 25 unique partner organizations across 13 countries — a broad reach explained by the characteristically large, pan-European consortium structure of MSCA programs. Their network is almost certainly dominated by academic research groups and universities, with a geographic spread across Western and Northern Europe.

What sets them apart

OSSDSIGN AB occupies an uncommon position as a small Swedish ceramics company with direct stakes in both fundamental fracture science and clinical implant applications — most industrial MSCA partners are either much larger corporations or purely application-focused. As an SME, they offer consortium builders a nimble industry partner who can provide real product context, rapid iteration on materials questions, and a clear commercial end-point that strengthens the societal impact narrative of research proposals. Their Uppsala base also places them within one of Scandinavia's strongest biomedical research clusters, giving access to clinical and academic networks that larger companies based elsewhere may not have.

Highlights from their portfolio

• NU-SPINE
  Directly maps to OSSDSIGN's core product domain — ceramic spinal implants — making this the clearest window into their commercial expertise and the research questions most relevant to their technology roadmap.
• FRAMED
  A cross-disciplinary fracture mechanics network spanning civil engineering, energy, and biomaterials that gave OSSDSIGN rare exposure to failure modeling methods outside their medical device niche.